Pub Date : 2026-02-02DOI: 10.1016/j.sleep.2026.108824
Shahrokh Javaheri , Scott W. McKane , Robin E. Germany
Background
It is well-known patients with atrial fibrillation (AF) have significant fatigue and impaired quality of life (QoL). Because central sleep apnea (CSA) could be associated with AF, CSA could be a contributory but treatable comorbidity.
Objectives
Retrospective assessment of the impact of CSA treatment with transvenous phrenic nerve stimulation (TPNS) on sleep and QoL in a subgroup of patients with CSA and AF from the remedē® System pivotal trial.
Methods
Patients were implanted with a TPNS device and randomized to treatment or control. Therapy was activated in the treatment arm and remained off in control for 6 months, when TPNS was also activated. Patients were followed through 12 months.
Results
Sixty-four of 151 implanted participants had AF, including 32 per arm. The apnea hypopnea index and central apnea index decreased significantly from medians of 49 and 20 events/hour of sleep at baseline to 21 and 1/hour after 6 months of TPNS therapy (p < 0.001 for each), respectively. In parallel, changes in arousal index (48 at baseline vs. 25/hour of sleep at 6 months, p < 0.001) and percent of sleep time with oxygen saturation less than 90% (8% vs. 4%, p = 0.071) improved. Compared to the control group, Patient Global Assessment and Epworth Sleepiness Scale improved significantly with treatment. Improvements were sustained for 12 months and results were similar in the control group after therapy activation.
Conclusions
AF was highly prevalent in patients with CSA. TPNS therapy may significantly improve sleep metrics, QoL, and daytime sleepiness in patients with CSA and AF.
{"title":"Changes in quality of life in patients with atrial fibrillation and central sleep apnea treated with transvenous phrenic nerve stimulation","authors":"Shahrokh Javaheri , Scott W. McKane , Robin E. Germany","doi":"10.1016/j.sleep.2026.108824","DOIUrl":"10.1016/j.sleep.2026.108824","url":null,"abstract":"<div><h3>Background</h3><div>It is well-known patients with atrial fibrillation (AF) have significant fatigue and impaired quality of life (QoL). Because central sleep apnea (CSA) could be associated with AF, CSA could be a contributory but treatable comorbidity.</div></div><div><h3>Objectives</h3><div>Retrospective assessment of the impact of CSA treatment with transvenous phrenic nerve stimulation (TPNS) on sleep and QoL in a subgroup of patients with CSA and AF from the <strong>rem</strong>edē® System pivotal trial.</div></div><div><h3>Methods</h3><div>Patients were implanted with a TPNS device and randomized to treatment or control. Therapy was activated in the treatment arm and remained off in control for 6 months, when TPNS was also activated. Patients were followed through 12 months.</div></div><div><h3>Results</h3><div>Sixty-four of 151 implanted participants had AF, including 32 per arm. The apnea hypopnea index and central apnea index decreased significantly from medians of 49 and 20 events/hour of sleep at baseline to 21 and 1/hour after 6 months of TPNS therapy (p < 0.001 for each), respectively. In parallel, changes in arousal index (48 at baseline vs. 25/hour of sleep at 6 months, p < 0.001) and percent of sleep time with oxygen saturation less than 90% (8% vs. 4%, p = 0.071) improved. Compared to the control group, Patient Global Assessment and Epworth Sleepiness Scale improved significantly with treatment. Improvements were sustained for 12 months and results were similar in the control group after therapy activation.</div></div><div><h3>Conclusions</h3><div>AF was highly prevalent in patients with CSA. TPNS therapy may significantly improve sleep metrics, QoL, and daytime sleepiness in patients with CSA and AF.</div></div><div><h3>Registration</h3><div>ClinicalTrials.gov identifier NCT01816776.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"141 ","pages":"Article 108824"},"PeriodicalIF":3.4,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146126570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sexsomnia is a NREM parasomnia characterized by involuntary sexual behavior during confusional arousal. Video examples are rare. Here we present the case of a man who was accused of sexually assaulting his girlfriend during the night but had no memory of doing so. During a video polysomnography, he masturbated in his sleep with his left hand during the N2 and N3 sleep stages, confirming sexsomnia. However, he always masturbated with his right hand when awake. Treatment with gabapentin did not alleviate sexsomnia and triggered obstructive sleep apnea, which improved when the treatment was replaced with paroxetine. The effect of paroxetine on sexsomnia was unknown. This case supports the concept of automatic behavior in sexsomnia.
{"title":"Left hand sleep masturbation in a right-handed male patient with sexsomnia","authors":"Mathilde Brice , Ana-Zenovia Gales , Valérie Attali , Mahaut Chauvin , Isabelle Arnulf","doi":"10.1016/j.sleep.2026.108823","DOIUrl":"10.1016/j.sleep.2026.108823","url":null,"abstract":"<div><div>Sexsomnia is a NREM parasomnia characterized by involuntary sexual behavior during confusional arousal. Video examples are rare. Here we present the case of a man who was accused of sexually assaulting his girlfriend during the night but had no memory of doing so. During a video polysomnography, he masturbated in his sleep with his left hand during the N2 and N3 sleep stages, confirming sexsomnia. However, he always masturbated with his right hand when awake. Treatment with gabapentin did not alleviate sexsomnia and triggered obstructive sleep apnea, which improved when the treatment was replaced with paroxetine. The effect of paroxetine on sexsomnia was unknown. This case supports the concept of automatic behavior in sexsomnia.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"141 ","pages":"Article 108823"},"PeriodicalIF":3.4,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146120049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.sleep.2026.108820
Joseph J. Knapik , Ryan A. Steelman , John A. Caldwell , Daniel W. Trone , Harris R. Lieberman
Objectives
This cross-sectional investigation examined associations between clinically diagnosed insomnia (CDI) and comorbid conditions in United States military service members (SMs).
Methods
A stratified random sample of SMs completed an on-line questionnaire assessing their demographic and lifestyle characteristics. Diagnosed medical conditions for a six-month period prior to questionnaire completion were obtained from a comprehensive military electronic medical surveillance system and grouped into 18 general (largely systemic) and 30 specific clinically diagnosed medical categories (CDMCs). CDMC prevalence odds was compared among those with (n = 771) and without (n = 25,909) CDI.
Results
After adjustments for potentially confounding demographic and lifestyle characteristics, CDI was associated with higher odds of a diagnosis in 17 of the general CDMCs and 26 of the specific CDMCs. The five general CDMCs with the largest differences between those with and without CDI were mental/behavioral diseases (odds ratio [OR] = 7.68, 95% confidence interval [95%CI] = 6.54–9.01), signs/symptoms/abnormal labs (OR = 4.99, 95%CI = 4.19–5.93), diseases of the musculoskeletal system (OR = 4.43, 95%CI = 3.72–5.28), endocrine/nutritional/metabolic diseases (OR = 2.97, 95%CI = 2.47–3.58), and diseases of the digestive system (OR = 2.68, 95%CI = 2.18–3.28). The five specific CDMCs with the highest adjusted odds among those with and without CDI were sleep-related movement disorder (OR = 14.68, 95%CI = 9.26–23.26), fibromyalgia (OR = 14.14, 95%CI = 5.74–34.80), post-traumatic stress disorder (OR = 12.94, 95%CI = 10.09–16.59), anxiety (OR = 9.40, 95%CI = 7.71–11.46), and traumatic brain injury (OR = 8.52, 95%CI = 5.93–12.24). Prevalence of CDI increased as the number of CDMCs increased: SMs with 0–1, 2–3, 4–5 and ≥6 general CDMCs had CDI prevalences of 0.5%, 3.2%, 6.7%, and 10.9%, respectively.
Conclusion
In a young, physically active population CDI was associated with many CDMCs involving multiple physiological systems.
{"title":"Many types of comorbidities are associated with clinically diagnosed insomnia in United States military service members","authors":"Joseph J. Knapik , Ryan A. Steelman , John A. Caldwell , Daniel W. Trone , Harris R. Lieberman","doi":"10.1016/j.sleep.2026.108820","DOIUrl":"10.1016/j.sleep.2026.108820","url":null,"abstract":"<div><h3>Objectives</h3><div>This cross-sectional investigation examined associations between clinically diagnosed insomnia (CDI) and comorbid conditions in United States military service members (SMs).</div></div><div><h3>Methods</h3><div>A stratified random sample of SMs completed an on-line questionnaire assessing their demographic and lifestyle characteristics. Diagnosed medical conditions for a six-month period prior to questionnaire completion were obtained from a comprehensive military electronic medical surveillance system and grouped into 18 general (largely systemic) and 30 specific clinically diagnosed medical categories (CDMCs). CDMC prevalence odds was compared among those with (n = 771) and without (n = 25,909) CDI.</div></div><div><h3>Results</h3><div>After adjustments for potentially confounding demographic and lifestyle characteristics, CDI was associated with higher odds of a diagnosis in 17 of the general CDMCs and 26 of the specific CDMCs. The five general CDMCs with the largest differences between those with and without CDI were mental/behavioral diseases (odds ratio [OR] = 7.68, 95% confidence interval [95%CI] = 6.54–9.01), signs/symptoms/abnormal labs (OR = 4.99, 95%CI = 4.19–5.93), diseases of the musculoskeletal system (OR = 4.43, 95%CI = 3.72–5.28), endocrine/nutritional/metabolic diseases (OR = 2.97, 95%CI = 2.47–3.58), and diseases of the digestive system (OR = 2.68, 95%CI = 2.18–3.28). The five specific CDMCs with the highest adjusted odds among those with and without CDI were sleep-related movement disorder (OR = 14.68, 95%CI = 9.26–23.26), fibromyalgia (OR = 14.14, 95%CI = 5.74–34.80), post-traumatic stress disorder (OR = 12.94, 95%CI = 10.09–16.59), anxiety (OR = 9.40, 95%CI = 7.71–11.46), and traumatic brain injury (OR = 8.52, 95%CI = 5.93–12.24). Prevalence of CDI increased as the number of CDMCs increased: SMs with 0–1, 2–3, 4–5 and ≥6 general CDMCs had CDI prevalences of 0.5%, 3.2%, 6.7%, and 10.9%, respectively.</div></div><div><h3>Conclusion</h3><div>In a young, physically active population CDI was associated with many CDMCs involving multiple physiological systems.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"141 ","pages":"Article 108820"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146171875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-31DOI: 10.1016/j.sleep.2026.108814
Laura Simon , Lena Sophia Steubl , Merritt Gossmann , Michael Stach , Yannik Terhorst , Julia Witte , Olaf Reis , Michael Kölch , Christoph Berger , Rüdiger Pryss , Harald Baumeister , Alexander Dück
Introduction
Access to cognitive behavioral therapy for insomnia (CBT-I) in children and adolescents is limited. Mobile health applications (MHAs) available in app stores may provide an accessible and scalable option for delivering CBT-I. This study systematically evaluated the quality of MHAs targeting insomnia in children and adolescents and examined their evidence base and treatment components.
Methods
In November 2024, a systematic search of the Google Play and Apple App Stores was conducted to identify MHAs targeting insomnia in children and adolescents. MHAs were screened for eligibility in a two-level process: first based on app store descriptions, then after downloading the MHA. Eligible MHAs were independently evaluated using the German Mobile Application Rating Scale (MARS-G), which rates MHAs from 1 (inadequate) to 5 (excellent) across the subscales engagement, functionality, aesthetics, and information. Additionally, the featured treatment components and supporting scientific evidence were assessed.
Results
Of 2341 MHAs initially identified, eight MHA products met the inclusion criteria. The overall quality was moderate (mean = 3.5, SD = 0.4). Among the subscales, functionality was rated highest (mean = 3.8, SD = 0.6), followed by aesthetics (mean = 3.6, SD = 0.6), engagement (mean = 3.3, SD = 0.4), and information (mean = 3.1, SD = 0.8). Sleep hygiene was the most commonly featured treatment component (seven MHA products). While scientific evidence was identified for five MHA products, none specifically evaluated insomnia in the target population.
Conclusion
Although many MHAs claim to target sleep in children and adolescents, few incorporate CBT-I components beyond sleep hygiene. The moderate quality and limited evidence base underscore the need for theory-driven, rigorously evaluated MHAs tailored to this age group.
{"title":"Swipe for sleep - a standardized evaluation of mobile health apps for insomnia in children and adolescents","authors":"Laura Simon , Lena Sophia Steubl , Merritt Gossmann , Michael Stach , Yannik Terhorst , Julia Witte , Olaf Reis , Michael Kölch , Christoph Berger , Rüdiger Pryss , Harald Baumeister , Alexander Dück","doi":"10.1016/j.sleep.2026.108814","DOIUrl":"10.1016/j.sleep.2026.108814","url":null,"abstract":"<div><h3>Introduction</h3><div>Access to cognitive behavioral therapy for insomnia (CBT-I) in children and adolescents is limited. Mobile health applications (MHAs) available in app stores may provide an accessible and scalable option for delivering CBT-I. This study systematically evaluated the quality of MHAs targeting insomnia in children and adolescents and examined their evidence base and treatment components.</div></div><div><h3>Methods</h3><div>In November 2024, a systematic search of the Google Play and Apple App Stores was conducted to identify MHAs targeting insomnia in children and adolescents. MHAs were screened for eligibility in a two-level process: first based on app store descriptions, then after downloading the MHA. Eligible MHAs were independently evaluated using the German Mobile Application Rating Scale (MARS-G), which rates MHAs from 1 (inadequate) to 5 (excellent) across the subscales engagement, functionality, aesthetics, and information. Additionally, the featured treatment components and supporting scientific evidence were assessed.</div></div><div><h3>Results</h3><div>Of 2341 MHAs initially identified, eight MHA products met the inclusion criteria. The overall quality was moderate (mean = 3.5, SD = 0.4). Among the subscales, functionality was rated highest (mean = 3.8, SD = 0.6), followed by aesthetics (mean = 3.6, SD = 0.6), engagement (mean = 3.3, SD = 0.4), and information (mean = 3.1, SD = 0.8). Sleep hygiene was the most commonly featured treatment component (seven MHA products). While scientific evidence was identified for five MHA products, none specifically evaluated insomnia in the target population.</div></div><div><h3>Conclusion</h3><div>Although many MHAs claim to target sleep in children and adolescents, few incorporate CBT-I components beyond sleep hygiene. The moderate quality and limited evidence base underscore the need for theory-driven, rigorously evaluated MHAs tailored to this age group.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"141 ","pages":"Article 108814"},"PeriodicalIF":3.4,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146120105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1016/j.sleep.2026.108813
Matteo Carpi , Daniel Ruivo Marques
The heterogeneity of insomnia presentations has long challenged research and clinical practice, motivating efforts to identify reliable disorder phenotypes. Person-centered, data-driven approaches such as latent class analysis (LCA) have provided new insights, suggesting that insomnia subtypes may differ not only in nocturnal symptoms but also in perceived impact and daytime distress. Despite this progress, LCA solutions often remain confined to the original datasets, limiting replication and applied use.
To address this gap, we developed the insomnia-LCA classifier, an open-source web application that assigns new Insomnia Severity Index (ISI) response profiles to one of four subtypes identified in a previously published LCA of Italian university students: no insomnia (NI), subthreshold insomnia (SI), high insomnia risk (HI), and predominant daytime symptoms (DS). Using the original model's class priors and item-level conditional response probabilities, the app computes posterior class probabilities from user-entered ISI responses, individually or in batch mode. Outputs include class probabilities and modal assignment, ISI total and subscale scores, and a visual comparison between the individual profile and subtype mean patterns.
Reclassification of the original dataset showed near-perfect agreement with the latent class model (accuracy = 0.999; Cohen's kappa = 0.999), and synthetic profiles behaved as expected. The insomnia-LCA classifier provides a practical, reproducible tool for deploying and testing LCA-derived phenotypes in clinical research.
{"title":"Insomnia-LCA classifier: an open web application for insomnia subtype classification using latent class analysis","authors":"Matteo Carpi , Daniel Ruivo Marques","doi":"10.1016/j.sleep.2026.108813","DOIUrl":"10.1016/j.sleep.2026.108813","url":null,"abstract":"<div><div>The heterogeneity of insomnia presentations has long challenged research and clinical practice, motivating efforts to identify reliable disorder phenotypes. Person-centered, data-driven approaches such as latent class analysis (LCA) have provided new insights, suggesting that insomnia subtypes may differ not only in nocturnal symptoms but also in perceived impact and daytime distress. Despite this progress, LCA solutions often remain confined to the original datasets, limiting replication and applied use.</div><div>To address this gap, we developed the <em>insomnia-LCA classifier</em>, an open-source web application that assigns new Insomnia Severity Index (ISI) response profiles to one of four subtypes identified in a previously published LCA of Italian university students: no insomnia (NI), subthreshold insomnia (SI), high insomnia risk (HI), and predominant daytime symptoms (DS). Using the original model's class priors and item-level conditional response probabilities, the app computes posterior class probabilities from user-entered ISI responses, individually or in batch mode. Outputs include class probabilities and modal assignment, ISI total and subscale scores, and a visual comparison between the individual profile and subtype mean patterns.</div><div>Reclassification of the original dataset showed near-perfect agreement with the latent class model (accuracy = 0.999; Cohen's kappa = 0.999), and synthetic profiles behaved as expected. The <em>insomnia-LCA classifier</em> provides a practical, reproducible tool for deploying and testing LCA-derived phenotypes in clinical research.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"141 ","pages":"Article 108813"},"PeriodicalIF":3.4,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-30DOI: 10.1016/j.sleep.2026.108818
Francy Cruz-Sanabria , Giovanni Cenerini , Simone Bruno , Raffaele Ferri , Simona Fiori , Ugo Faraguna
Introduction
Melatonin plays a key role in sleep regulation. Combining melatonin with its precursors, L-tryptophan (LT) and 5-Hydroxytryptophan (5HTP), may influence sleep-related outcomes, but evidence in children with neurodevelopmental disorders (NDDs) is limited. This exploratory study compares the effects of melatonin combined with 5HTP (M-5HTP) and melatonin combined with LT (M-LT) on sleep disorders in children with NDDs.
Methods
This single-center, randomized pilot comparative trial involved children under five years of age with NDDs free of sleep-inducing drugs. Baseline evaluations and actigraphy monitoring were performed. Children were randomly assigned to either M-5HTP (1 mg Melatonin +10 mg 5HTP) or M-LT (1 mg Melatonin +20 mg LT) treatment at 8 p.m. for at least four weeks. Post-treatment actigraphy monitoring assessed sleep parameters.
Results
Of 51 screened children, 26 were enrolled and 13 completed the study (M-5HTP: 9, M-LT: 4). No statistically significant between-group differences in change scores were observed. Within-group analyses showed a significant reduction in the Sleep Movement Index (SMI) from baseline to follow-up in the M-5HTP group (T0: 6.55; T1: 1.25; p=0.006), whereas no significant changes were observed in the M-LT group.
Discussion
In this exploratory pilot study, a within-group reduction in nocturnal motor activity was observed among M-5HTP completers. Given the small sample size, high attrition rate, and limited statistical power, these findings should be interpreted cautiously and considered hypothesis-generating.
{"title":"Effect of melatonin enriched with L-Tryptophan and 5-Hydroxytryptophan on sleep parameters in children with neurodevelopmental disorders","authors":"Francy Cruz-Sanabria , Giovanni Cenerini , Simone Bruno , Raffaele Ferri , Simona Fiori , Ugo Faraguna","doi":"10.1016/j.sleep.2026.108818","DOIUrl":"10.1016/j.sleep.2026.108818","url":null,"abstract":"<div><h3>Introduction</h3><div>Melatonin plays a key role in sleep regulation. Combining melatonin with its precursors, L-tryptophan (LT) and 5-Hydroxytryptophan (5HTP), may influence sleep-related outcomes, but evidence in children with neurodevelopmental disorders (NDDs) is limited. This exploratory study compares the effects of melatonin combined with 5HTP (M-5HTP) and melatonin combined with LT (M-LT) on sleep disorders in children with NDDs.</div></div><div><h3>Methods</h3><div>This single-center, randomized pilot comparative trial involved children under five years of age with NDDs free of sleep-inducing drugs. Baseline evaluations and actigraphy monitoring were performed. Children were randomly assigned to either M-5HTP (1 mg Melatonin +10 mg 5HTP) or M-LT (1 mg Melatonin +20 mg LT) treatment at 8 p.m. for at least four weeks. Post-treatment actigraphy monitoring assessed sleep parameters.</div></div><div><h3>Results</h3><div>Of 51 screened children, 26 were enrolled and 13 completed the study (M-5HTP: 9, M-LT: 4). No statistically significant between-group differences in change scores were observed. Within-group analyses showed a significant reduction in the Sleep Movement Index (SMI) from baseline to follow-up in the M-5HTP group (T0: 6.55; T1: 1.25; p=0.006), whereas no significant changes were observed in the M-LT group.</div></div><div><h3>Discussion</h3><div>In this exploratory pilot study, a within-group reduction in nocturnal motor activity was observed among M-5HTP completers. Given the small sample size, high attrition rate, and limited statistical power, these findings should be interpreted cautiously and considered hypothesis-generating.</div></div>","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"141 ","pages":"Article 108818"},"PeriodicalIF":3.4,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146126589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-29DOI: 10.1016/j.sleep.2025.106915
M. Varma
{"title":"Effect of sex hormones on sleep architecture in older women","authors":"M. Varma","doi":"10.1016/j.sleep.2025.106915","DOIUrl":"10.1016/j.sleep.2025.106915","url":null,"abstract":"","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"138 ","pages":"Article 106915"},"PeriodicalIF":3.4,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146070748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-29DOI: 10.1016/j.sleep.2025.106935
S. Qin , J.L. Ong , K.F. Wong , T. Liang , E.K.K. Ng , W.-P. Koh , J.H. Zhou , M.W.L. Chee
{"title":"Trait-Like Slow-Wave Activities Link to Cognition: Multi-Night At-Home Wireless EEG Study in Older Adults","authors":"S. Qin , J.L. Ong , K.F. Wong , T. Liang , E.K.K. Ng , W.-P. Koh , J.H. Zhou , M.W.L. Chee","doi":"10.1016/j.sleep.2025.106935","DOIUrl":"10.1016/j.sleep.2025.106935","url":null,"abstract":"","PeriodicalId":21874,"journal":{"name":"Sleep medicine","volume":"138 ","pages":"Article 106935"},"PeriodicalIF":3.4,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146070790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号